Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers

NCT07071649 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire, Amiens as lead sponsor.

NCT NCT07071649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07071649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Not applicable
Overall status
Recruiting
Start date
November 20, 2025
Completion date
February 28, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, biomarkers, non-invasive diagnosis, phosphorylated protein p-tau217